Efficacy of Transcranial Direct Current Stimulation (tDCS) in Patients Suffering From Pathological Use of Internet Gaming

NCT ID: NCT04120714

Last Updated: 2024-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-06

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Internet has grown considerably in the last twenty years, and as a result, cases of excessive iinterney use have emerged. These cases, which have clinical similarities with substance addiction, involve the various activities related to the Internet (online gambling, discussion forums, online networking, e-mail, pornography, shopping, etc.). However, to date, only the pathological use of Internet gaming (PUIG) is referenced in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5, section III).

In PUIG, an individual loses control when gambling online. He/she typically spends 8 to 10 hours on this activity, sometimes without eating or sleeping. Usual obligations, such as school or work, or family obligations are neglected. PUIG can cause great psychological and social suffering. Neurological complications (epilepsy) and deaths (cardiac arrest) related to PUIG have also been reported. These situations are all the more dramatic because they often affect adolescents and young adults. In Asia, PUIG has become a public health problem. To date, no treatment has been validated for this disorder.

Non-invasive brain stimulation (NIBS) techniques can modulate neural activity in the dorsolateral prefrontal cortex (DLPFC). This modulation makes it possible to reduce addictive behaviours through different mechanisms (reduction of craving, impulsivity, and decision-making disorders). These techniques could be effective for PUIG.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pathological Use of Internet Games

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo tDCS group

Inactive tDCS

Group Type PLACEBO_COMPARATOR

Placebo tDCS

Intervention Type DEVICE

inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions

Questionnaires

Intervention Type OTHER

* visual analogue scale (VAS)
* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)
* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)
* Go-No go test
* HAM-D scale
* SF-12 quality of life scale

Active tDCS group

Active tDCS

Group Type EXPERIMENTAL

Active tDCS

Intervention Type DEVICE

active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions

Questionnaires

Intervention Type OTHER

* visual analogue scale (VAS)
* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)
* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)
* Go-No go test
* HAM-D scale
* SF-12 quality of life scale

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active tDCS

active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions

Intervention Type DEVICE

Placebo tDCS

inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions

Intervention Type DEVICE

Questionnaires

* visual analogue scale (VAS)
* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)
* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)
* Go-No go test
* HAM-D scale
* SF-12 quality of life scale

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged ≥ 12 years old
* Patient and/or parents who have given oral consent
* Patient with PUIG (DSM-5 criteria)
* Patient that is motivated and willing to reduce or stop internet gaming

Exclusion Criteria

* a person who is not affiliated to or not a beneficiary of a social security scheme
* Patient with severe chronic psychiatric comorbidity (schizophrenia, paranoia, chronic hallucinatory psychosis) and bipolar disorder types I and II
* Patient with a gambling addiction
* Patient who has had a recent change (\< 1 month) in the prescription of psychotropic treatment
* Patient with an addiction to a psychoactive substance other than tobacco
* Patient receiving psychiatric care without consent or legal protection (guardianship, curatorship)
* Minor patient without parental consent for care
* Patient with severe heart, kidney, liver or lung failure
* Patient with a contraindication to the practice of tDCS: metal parts, medical devices implanted in the brain
* Pregnancy or breastfeeding in progress (negative pregnancy test)
* Patient unable to commit to a three-month follow-up
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de DIJON

Dijon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Benoît TROJAK

Role: CONTACT

03.80.29.37.69 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Benoît TROJAK

Role: primary

3 80 29 37 69 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TROJAK 2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.